MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ROIV stock logo

ROIV

Roivant Sciences Ltd.

$29.05
0.56
 (1.97%)
Exchange:  NASDAQ
Market Cap:  20.895B
Shares Outstanding:  215.353M
Delayed data
Calculate ROIV Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Matthew Gline
Full Time Employees:  908
Address: 
11-12 St. James’s Square
London
SW1Y 4LB
GB
Website:  https://roivant.com
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm’s development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/08/11 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue32,71329,0538,260
Gross Profit31,11428,1426,975
EBITDA-802,892-1,099,610-1,281,955
Operating Income-824,928-1,113,681-1,285,303
Net Income4,348,926-171,981-299,771

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets7,222,4825,436,9405,708,687
Total Liabilities773,953249,742416,275
Total Stockholders Equity5,968,5814,687,6054,527,370
Total Debt499,749100,170107,438
Cash and Cash Equivalents6,535,7062,715,4111,419,232

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-765,268-765,268-750,349
Capital Expenditure-1,382-1,382-8,209
Free Cash Flow-766,650-766,650-758,558
Net Income4,231,2064,231,206-397,907
Net Change in Cash4,858,3354,858,335-1,294,679

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,701,095.290Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)11,646,727.617Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)4,696,503.500Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-11,646,727.617Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-1,701,095.290Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-4,696,503.500Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)280,390.656Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)4,797,983.029Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)1,640,989.615Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)45,304,674.101Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)310,183,210.860Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)125,080,330.145Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)2.370Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)6.910Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.400Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)6Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
124.795M  ?P/S
 (TTM)
: 
2488.71
?Net Income
 (TTM)
: 
4.349B  ?P/E
 (TTM)
: 
-66.94
?Enterprise Value
 (TTM)
: 
19.241B  ?EV/FCF
 (TTM)
: 
-25.37
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
?ROE
 (TTM)
: 
  ?ROIC
 (TTM)
: 
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
?P/B
 (TTM)
: 
  ?Current Ratio
 (TTM)
: 

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ROIV valuation

Is ROIV (ROIV) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for ROIV (ROIV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ROIV a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ROIV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ROIV’s P/E ratio?

You can see ROIV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ROIV?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ROIV a good long-term investment?

Whether ROIV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ROIV

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.97
MARKETSnap

Trading Metrics:

Open: 28.92   Previous Close: 28.49
Day Low: 28.31   Day High: 29.31
Year Low: 10.71   Year High: 32.79
Price Avg 50: 28.74   Price Avg 200: 22.83
Volume: 3.459M   Average Volume: 5.837M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free

ROIV full analysis

26/11/2025

Welcome to MARKETSNAP’s SWOT analysis for Roivant Sciences Ltd., a company that might not be on everyone’s radar but is definitely worth a deep dive for long-term investors like us. If you’re looking to build wealth over time with smart picks, let’s unpack what makes this biotech player tick, where it’s shining, where it’s stumbling, and what could shape its future. Stick with me as we break down the strengths, weaknesses, opportunities, and threats for Roivant Sciences, along with some…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Login — it's free

See in Nexus

Relevant news

Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
09-06-2026 20:22
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
29-05-2026 17:24
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
20-05-2026 18:20
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Q4 Earnings Call Highlights
20-05-2026 10:08
Roivant Sciences Q4 Earnings Call Highlights
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
20-05-2026 09:15
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
19-05-2026 13:01
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read